10-K: Aligos Therapeutics Reports 2024 Financial Results and Provides Business Update

Aligos Therapeutics, a clinical-stage biotechnology company, details its financial performance for 2024 and outlines progress in its liver disease and viral infection programs in its 10K filing.

Summary

• Aligos Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for liver diseases and viral infections.
• The company's pipeline includes drug candidates for chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), and coronavirus infections.
• ALG000184, a Capsid Assembly Modulator (CAME) for chronic HBV infection, has shown promising results in Phase 1 clinical trials, demonstrating greater HBV DNA suppression compared to standard treatments.
• ALG055009, a thyroid hormone receptor beta (THR) agonist for MASH, met the primary endpoint in a Phase 2a study, achieving statistically significant reductions in liver fat.
• ALG097558, a coronavirus 3CL protease inhibitor, is in clinical studies for COVID-19 treatment and has shown potential for ritonavir-free dosing.
• The company reported a net loss of $131.2 million for the year ended December 31, 2024, and had cash, cash equivalents, and investments of $56.9 million as of the same date.
• Aligos expects its current resources to fund operations for at least the next 12 months and is exploring options for additional funding, including potential out-licensing.
• The company is pursuing a strategy to develop pharmacologically optimized drug candidates and expand its pipeline through internal discovery and external collaborations.

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While there are positive clinical results and ongoing research, the company's financial losses and need for additional funding create uncertainty. The termination of the Merck collaboration is also a negative factor.

Positives

• ALG000184 has the potential to replace standard of care NA treatment and become the backbone of next-generation treatments.
• ALG055009 has the potential to become a best-in-class THR b agonist and could play an integral role in future combination regimens for MASH.
• ALG097558 has broad pan-coronavirus activity and does not require ritonavir boosting.
• The company has a management team with a proven track record of success in drug discovery and development.
• The company has secured licenses for technology from Emory, Luxna and AM Chemicals.

Negatives

• The company has incurred significant losses since inception and expects to continue to incur losses for the next several years.
• The company has never generated revenue from product sales and may never be profitable for a full fiscal year.
• The company will require substantial additional financing to achieve its goals, which may not be available on acceptable terms, or at all.
• The company is early in its development efforts, and its business is dependent on the successful development of its current and future drug candidates.
• The company faces significant competition, and if its competitors develop and market products that are more effective, safer or less expensive than the drug candidates it develops, its commercial opportunities will be negatively impacted.
• Merck provided Aligos written notice of termination for both of the targets in the collaboration.

Risks

• Clinical trials may be delayed or halted due to undesirable side effects or other properties of drug candidates.
• Collaborations with third parties may not be successful, hindering the market potential of drug candidates.
• The company may face legal proceedings alleging infringement of intellectual property rights.
• Failure to comply with obligations in licensing agreements could harm the company's competitive position.
• The company is highly dependent on key personnel, and failure to retain them could impede business strategy implementation.
• The company's operating results may fluctuate significantly, making future results difficult to predict.
• Health pandemics or epidemics could disrupt the company's business and delay clinical programs.
• The company may be unable to produce a therapy that successfully treats CHB, MASH or COVID-19.
• The company may be unable to obtain regulatory approval for and successfully commercialize its drug candidates.
• The company may be subject to product liability lawsuits.
• Healthcare legislative reform measures may have a material adverse effect on the company's business and results of operations.
• The company may be subject to federal, state and foreign data privacy and security laws and regulations.
• The company's information technology systems, or those used by its CROs or other contractors or consultants, may fail or suffer security breaches.
• The company may be subject to claims challenging the inventorship of its patents and other intellectual property.
• The company may not be able to protect its intellectual property rights throughout the world.
• Changes in patent law could diminish the value of patents in general, thereby impairing the company's ability to protect its drug candidates.
• The company may become involved in lawsuits to protect or enforce its patents or other intellectual property, which could be expensive, time-consuming and unsuccessful.
• The company may be subject to claims by third parties asserting that it or its employees have infringed, misappropriated or otherwise violated their intellectual property rights, or claiming ownership of what the company regards as its own intellectual property.
• The company may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might subject it to infringement claims or adversely affect its ability to develop and market its drug candidates.
• The company may not be successful in its efforts to identify or discover other drug candidates and may fail to capitalize on programs or drug candidates that may present a greater commercial opportunity or for which there is a greater likelihood of success.
• The company may seek and fail to obtain fast track or breakthrough therapy designations from the FDA for its current or future drug candidates or priority review designation for any NDA it may submit to the FDA.
• The company may be required to make significant payments under its license agreements with Emory University, KU Leuven, and Luxna Biotech Co., Ltd.
• The company may be required to make significant payments under its license agreements with Emory University, KU Leuven, and Luxna Biotech Co., Ltd.
• The company may be subject to certain U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations, violations of which can have serious negative consequences for its business.
• The company's ability to utilize its net operating loss carryforwards and certain other tax attributes may be limited.
• If securities analysts do not publish research or reports about the company's business or if they publish negative evaluations of its stock, the price of its stock could decline.
• If the company fails to implement and maintain proper and effective internal control over financial reporting, its ability to produce accurate and timely financial statements could be impaired, investors may lose confidence in its financial reporting and the trading price of its common stock may decline.
• Provisions in the company's charter documents and under Delaware law could discourage a takeover that stockholders may consider favorable and may lead to entrenchment of management.
• Claims for indemnification by the company's directors and officers may reduce its available funds to satisfy successful third-party claims against it and may reduce the amount of money available to it.
• The company's amended and restated certificate of incorporation provides for an exclusive forum in the Court of Chancery of the State of Delaware for certain disputes between the company and its stockholders, which could limit its stockholders ability to obtain a favorable judicial forum for disputes with the company or its directors, officers or employees.

Future Outlook

Aligos expects its current resources to fund operations for at least the next 12 months and is exploring options for additional funding, including potential out-licensing. Dosing in HBeAg+/subjects will continue through 2025, with 96-week safety, PK, and antiviral activity data to be presented at upcoming scientific conferences. An exploratory combination study with mipeginterferon alfa2b is expected to begin in 2025. In addition, enabling activities for a randomized, doubleblind, active controlled Phase 2 study of monotherapy with ALG000184 vs. tenofovir disoproxil fumarate in HBeAg+ and HBeAgsubjects are underway, with the Phase 2 study expected to begin in mid-2025. Phase 2b enabling activities are underway, with expected completion in mid-2025. We are also assessing potential Phase 2b clinical trial study designs with key opinion leaders. Lastly, we are evaluating a variety of options to fund continued development, including potential out-licensing. NIAID is also sponsoring a drugdrug interaction and relative bioavailability study in healthy volunteers expected to start dosing in the second quarter of 2025. We expect that future development of ALG097558, including ongoing Phase 2 enabling activities, will be funded by external sources, including public funding sources as described below.

Management Comments

• The Aligos team has a demonstrated track record of success in drug development and medicinal chemistry in liver and viral diseases, resulting in three potential bestinclass drug candidates.

Industry Context

The document highlights the competitive landscape in the pharmaceutical industry, particularly in the areas of chronic HBV infection, MASH, and coronavirus treatments, noting that many competitors have greater resources and experience.

Comparison to Industry Standards

• ALG000184 is compared to standard of care nucleos(t)ide analogs (NAs) and competitor CAME drugs, demonstrating greater HBV DNA suppression.
• ALG055009 is compared to competitor THR agonists, showing enhanced pharmacologic properties.
• ALG097558 is compared to nirmatrelvir, demonstrating 3-fold more potency in cell-based assays.
• The document references resmetirom, a THR agonist approved for MASH, and discusses ALG055009's potential advantages.
• The document references Paxlovid and molnupiravir as competitors in the COVID-19 treatment space.

Stakeholder Impact

• Shareholders face potential dilution from future equity offerings.
• Employees' job security is linked to the company's financial stability and research success.
• Patients may benefit from the development of new therapies for liver diseases and viral infections.
• Suppliers and manufacturers are subject to the company's ability to fund its research and development programs.
• Creditors face risks associated with the company's ability to repay its debts.

Next Steps

• Continue dosing in HBeAg+/subjects through 2025, with 96-week safety, PK, and antiviral activity data to be presented at upcoming scientific conferences.
• Begin an exploratory combination study with mipeginterferon alfa2b in 2025.
• Begin a randomized, double-blind, active controlled Phase 2 study of monotherapy with ALG000184 vs. tenofovir disoproxil fumarate in HBeAg+ and HBeAgsubjects in mid-2025.
• Complete Phase 2b enabling activities for ALG055009 in mid-2025.
• Assess potential Phase 2b clinical trial study designs with key opinion leaders.
• Evaluate a variety of options to fund continued development of ALG055009, including potential out-licensing.
• Start dosing in a drugdrug interaction and relative bioavailability study in healthy volunteers in the second quarter of 2025.

Key Dates